Literature DB >> 19882420

Cognitive change in patients with Huntington disease on the Repeatable Battery for the Assessment of Neuropsychological Status.

Leigh J Beglinger1, Kevin Duff, Jessica Allison, Danielle Theriault, Justin J F O'Rourke, Anne Leserman, Jane S Paulsen.   

Abstract

Huntington disease (HD) is a neurodegenerative disease associated with cognitive, motor, and psychiatric deterioration over time. Although there is currently no cure for HD, there has been a surge of clinical trials available to patients with HD over the past 5 years. However, cognitive measures have generally been lacking from these trials. A brief, repeatable neuropsychological battery is needed to assess cognitive endpoints. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) may be useful for assessing change in interventional studies or for clinical monitoring. A total of 38 patients with HD were assessed using the RBANS, other cognitive tests, and the standardized HD battery (Unified Huntington's Disease Rating Scale, UHDRS) at two clinic visits approximately 16 months apart. The RBANS Attention Index, as well as individual subtest scores on Coding, Digit Span, List Recognition, Figure Copy, and Figure Recall all declined significantly over this interval. Performance on the UHDRS cognitive tests (Symbol Digit Modalities; Stroop Color, and Stroop Word) also declined, as did functional capacity. Results suggest that cognitive changes were detected both on established cognitive tasks used in HD research and on the RBANS in patients with measurable functional decline. The RBANS provided additional information about other cognitive domains affected (e.g., memory) and may be a useful measure for tracking longitudinal change.

Entities:  

Mesh:

Year:  2009        PMID: 19882420      PMCID: PMC3806302          DOI: 10.1080/13803390903313564

Source DB:  PubMed          Journal:  J Clin Exp Neuropsychol        ISSN: 1380-3395            Impact factor:   2.475


  35 in total

1.  Brain structure in preclinical Huntington's disease.

Authors:  Jane S Paulsen; Vince A Magnotta; Ania E Mikos; Henry L Paulson; Elizabeth Penziner; Nancy C Andreasen; Peg C Nopoulos
Journal:  Biol Psychiatry       Date:  2005-08-22       Impact factor: 13.382

2.  Episodic memory impairment in Huntington's disease: a meta-analysis.

Authors:  Alonso Montoya; Marc Pelletier; Matthew Menear; Elisabeth Duplessis; François Richer; Martin Lepage
Journal:  Neuropsychologia       Date:  2006-06-23       Impact factor: 3.139

3.  The subcortical dementia of Huntington's disease.

Authors:  K K Zakzanis
Journal:  J Clin Exp Neuropsychol       Date:  1998-08       Impact factor: 2.475

4.  Probability of obsessive and compulsive symptoms in Huntington's disease.

Authors:  Leigh J Beglinger; Douglas R Langbehn; Kevin Duff; Laura Stierman; Donald W Black; Carissa Nehl; Karen Anderson; Elizabeth Penziner; Jane S Paulsen
Journal:  Biol Psychiatry       Date:  2006-07-12       Impact factor: 13.382

5.  A four-year prospective study of cognitive functioning in Huntington's disease.

Authors:  Julianna Ward; Jeannie-Marie Sheppard; Barnett Shpritz; Russell L Margolis; Adam Rosenblatt; Jason Brandt
Journal:  J Int Neuropsychol Soc       Date:  2006-07       Impact factor: 2.892

6.  White matter volume and cognitive dysfunction in early Huntington's disease.

Authors:  Leigh J Beglinger; Peg C Nopoulos; Ricardo E Jorge; Douglas R Langbehn; Ania E Mikos; David J Moser; Kevin Duff; Robert G Robinson; Jane S Paulsen
Journal:  Cogn Behav Neurol       Date:  2005-06       Impact factor: 1.600

7.  Verbal episodic memory declines prior to diagnosis in Huntington's disease.

Authors:  Andrea C Solomon; Julie C Stout; Shannon A Johnson; Douglas R Langbehn; Elizabeth H Aylward; Jason Brandt; Christopher A Ross; Leigh Beglinger; Michael R Hayden; Karl Kieburtz; Elise Kayson; Elaine Julian-Baros; Kevin Duff; Mark Guttman; Martha Nance; David Oakes; Ira Shoulson; Elizabeth Penziner; Jane S Paulsen
Journal:  Neuropsychologia       Date:  2007-01-09       Impact factor: 3.139

Review 8.  Pharmacological management of Huntington's disease: an evidence-based review.

Authors:  Raphael M Bonelli; Gregor K Wenning
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

9.  The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity.

Authors:  C Randolph; M C Tierney; E Mohr; T N Chase
Journal:  J Clin Exp Neuropsychol       Date:  1998-06       Impact factor: 2.475

10.  Predictors of diagnosis in Huntington disease.

Authors:  Douglas R Langbehn; Jane S Paulsen
Journal:  Neurology       Date:  2007-05-15       Impact factor: 9.910

View more
  10 in total

Review 1.  Progress in developing transgenic monkey model for Huntington's disease.

Authors:  Brooke R Snyder; Anthony W S Chan
Journal:  J Neural Transm (Vienna)       Date:  2017-11-10       Impact factor: 3.575

2.  Effort in acute traumatic brain injury: considering more than pass/fail.

Authors:  Sara M Lippa; Kristina A Agbayani; Samuel Hawes; Emily Jokic; Jerome S Caroselli
Journal:  Rehabil Psychol       Date:  2014-08

3.  Deficits in stepping response time are associated with impairments in balance and mobility in people with Huntington disease.

Authors:  Allon Goldberg; Stacey L Schepens; Shawna M E Feely; James Y Garbern; Lindsey J Miller; Carly E Siskind; Gerry E Conti
Journal:  J Neurol Sci       Date:  2010-11-15       Impact factor: 3.181

4.  The RBANS Effort Index: base rates in geriatric samples.

Authors:  Kevin Duff; Cynthia C Spering; Sid E O'Bryant; Leigh J Beglinger; David J Moser; John D Bayless; Kennith R Culp; James W Mold; Russell L Adams; James G Scott
Journal:  Appl Neuropsychol       Date:  2011-01

5.  Understanding patient-reported outcome measures in Huntington disease: at what point is cognitive impairment related to poor measurement reliability?

Authors:  N E Carlozzi; S Schilling; A L Kratz; J S Paulsen; S Frank; J C Stout
Journal:  Qual Life Res       Date:  2018-06-16       Impact factor: 4.147

6.  Cognitive reserve and brain reserve in prodromal Huntington's disease.

Authors:  Aaron Bonner-Jackson; Jeffrey D Long; Holly Westervelt; Geoffrey Tremont; Elizabeth Aylward; Jane S Paulsen
Journal:  J Int Neuropsychol Soc       Date:  2013-05-23       Impact factor: 2.892

7.  Reliability and validity of the Repeatable Battery for the Assessment of Neuropsychological Status in community-dwelling elderly.

Authors:  Yan Cheng; Wenyuan Wu; Jiaqi Wang; Wei Feng; Xiangwei Wu; Chunbo Li
Journal:  Arch Med Sci       Date:  2011-11-08       Impact factor: 3.318

8.  No evidence of impaired gastric emptying in early Huntington's Disease.

Authors:  Carsten Saft; Jürgen Andrich; Marc Fälker; Sarah Gauda; Sina Küchler; Dirk Woitalla; Oliver Goetze
Journal:  PLoS Curr       Date:  2011-10-25

9.  Functional connectivity abnormalities in Type I Chiari: associations with cognition and pain.

Authors:  Michelle L Houston; James R Houston; Ken Sakaie; Petra M Klinge; Sarel Vorster; Mark Luciano; Francis Loth; Philip A Allen
Journal:  Brain Commun       Date:  2021-06-14

10.  Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease.

Authors:  Julie C Stout; Rebecca Jones; Izelle Labuschagne; Alison M O'Regan; Miranda J Say; Eve M Dumas; Sarah Queller; Damian Justo; Rachelle Dar Santos; Allison Coleman; Ellen P Hart; Alexandra Dürr; Blair R Leavitt; Raymund A Roos; Doug R Langbehn; Sarah J Tabrizi; Chris Frost
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-05-07       Impact factor: 10.154

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.